NTLA - Prime Medicine Stock: Only For The Most Patient Of Investors

2024-06-20 16:14:49 ET

Summary

• We take our first look at gene editing concern Prime Medicine, Inc., whose stock was recently upgraded by Citigroup.
• The company has an extensive set of potential candidates in pre-clinical research and just advanced its first gene therapy asset in clinical stage development.
• An analysis around Prime Medicine follows in the paragraphs below.

Today, we put Prime Medicine, Inc. ( PRME ) in the spotlight for the first time. The stock was upgraded to a Buy at Citigroup a month ago based on valuation and the company's pipeline. Therefore, it seemed a good time to see what this recent clinical-stage gene therapy has in development and whether the stock merits investment consideration. An analysis follows below....

For further details see: